- Conditions
- Erythema Multiforme
- Interventions
- Apremilast
- Drug
- Lead sponsor
- Robert Micheletti
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 148
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
- Interventions
- Maskin Probe
- Device
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Unintentional Ingestion of Prescriptions Within Vials and Blisters
- Interventions
- Visual distractor
- Other
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 2 Years to 54 Months
- Enrollment
- 229 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- East Lansing, Michigan • Howell, Michigan • Toledo, Ohio
- Conditions
- Inflammation; Skin, Resolution, Blister
- Interventions
- Lovaza, Cantharone, Phlebotomy
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epidermolysis Bullosa
- Interventions
- Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • New York, New York
- Conditions
- Epidermolysis Bullosa (EB)
- Interventions
- SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Drug
- Lead sponsor
- Paradigm Therapeutics
- Industry
- Eligibility
- 28 Days to 12 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Charleston, South Carolina
- Conditions
- Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
- Interventions
- Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
- Interventions
- Helicoll, Standard of Care Dressings
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Pemphigus Vulgaris
- Interventions
- VAY736, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Pemphigus Foliaceus, Pemphigus Vulgaris
- Interventions
- Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- Survey
- Other
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cranbury, New Jersey
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
- Biological
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2037
- U.S. locations
- 5
- States / cities
- Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Interventions
- Sirolimus, 2%, Vehicle
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Epidermolysis Bullosa, Epidermolysis Bullosa Simplex
- Interventions
- diacerein 1% ointment
- Drug
- Lead sponsor
- Castle Creek Pharmaceuticals, LLC
- Industry
- Eligibility
- 6 Months to 99 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
- Interventions
- LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Interventions
- AB-101, Rituximab, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- IRIS Research and Development, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Plantation, Florida
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- AGLE-102
- Drug
- Lead sponsor
- Aegle Therapeutics
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- Diacerein 1% Ointment
- Drug
- Lead sponsor
- Castle Creek Pharmaceuticals, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- Stevens-Johnson Syndrome, Corneal Blindness
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Interventions
- RGN-137, Placebo
- Drug
- Lead sponsor
- Lenus Therapeutics, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
- Conditions
- Epidermolysis Bullosa Simplex, Pachyonychia Congenita
- Interventions
- Jojoba oil with broccoli sprout extract, Jojoba oil (placebo)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epidermolysis Bullosa, Pruritus
- Interventions
- VPD-737, Placebo
- Drug · Other
- Lead sponsor
- Jean Yuh Tang
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California